Rakovina Therapeutics Past Earnings Performance
Past criteria checks 0/6
Rakovina Therapeutics's earnings have been declining at an average annual rate of -32.6%, while the Biotechs industry saw earnings growing at 13.8% annually.
Key information
-32.6%
Earnings growth rate
12.4%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | n/a |
| Return on equity | -58.6% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Rakovina Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -3 | 1 | 2 |
| 30 Jun 23 | 0 | -3 | 1 | 2 |
| 31 Mar 23 | 0 | -3 | 1 | 2 |
| 31 Dec 22 | 0 | -3 | 1 | 2 |
| 30 Sep 22 | 0 | -3 | 1 | 2 |
| 30 Jun 22 | 0 | -3 | 1 | 2 |
| 31 Mar 22 | 0 | -3 | 1 | 2 |
| 31 Dec 21 | 0 | -6 | 1 | 2 |
| 30 Sep 21 | 0 | -5 | 1 | 1 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Quality Earnings: RKV is currently unprofitable.
Growing Profit Margin: RKV is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RKV is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare RKV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RKV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: RKV has a negative Return on Equity (-58.65%), as it is currently unprofitable.